Annual Operating Profit
-$27.14 M
+$24.05 M+46.98%
December 31, 2023
Summary
- As of February 12, 2025, QNCX annual operating income is -$27.14 million, with the most recent change of +$24.05 million (+46.98%) on December 31, 2023.
- During the last 3 years, QNCX annual operating profit has risen by +$51.75 million (+65.60%).
- QNCX annual operating profit is now -161.74% below its all-time high of -$10.37 million, reached on December 31, 2017.
Performance
QNCX Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Profit
-$8.55 M
+$296.00 K+3.35%
September 30, 2024
Summary
- As of February 12, 2025, QNCX quarterly operating income is -$8.55 million, with the most recent change of +$296.00 thousand (+3.35%) on September 30, 2024.
- Over the past year, QNCX quarterly operating profit has dropped by -$203.00 thousand (-2.43%).
- QNCX quarterly operating profit is now -223.34% below its all-time high of -$2.64 million, reached on June 30, 2018.
Performance
QNCX Quarterly Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM Operating Profit
-$34.40 M
-$2.45 M-7.67%
September 30, 2024
Summary
- As of February 12, 2025, QNCX TTM operating income is -$34.40 million, with the most recent change of -$2.45 million (-7.67%) on September 30, 2024.
- Over the past year, QNCX TTM operating profit has dropped by -$7.33 million (-27.06%).
- QNCX TTM operating profit is now -1146.52% below its all-time high of -$2.76 million, reached on March 31, 2018.
Performance
QNCX TTM Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Profit Formula
Operating Profit = Gross Profit − Operating Expenses
QNCX Operating Profit Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +47.0% | -2.4% | -27.1% |
3 y3 years | +65.6% | -2.4% | -27.1% |
5 y5 years | -124.0% | -2.4% | -27.1% |
QNCX Operating Profit Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | at high | +70.0% | -53.0% | +63.7% | -37.3% | +61.9% |
5 y | 5-year | at high | +70.0% | -53.0% | +63.7% | -37.3% | +61.9% |
alltime | all time | -161.7% | +70.0% | -223.3% | +63.7% | -1146.5% | +61.9% |
Quince Therapeutics Operating Profit History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | -$8.55 M(-3.3%) | -$34.40 M(+7.7%) |
Jun 2024 | - | -$8.84 M(+1.9%) | -$31.95 M(+11.4%) |
Mar 2024 | - | -$8.67 M(+4.0%) | -$28.69 M(+6.0%) |
Dec 2023 | -$27.14 M(-47.0%) | -$8.34 M(+36.9%) | -$27.08 M(+8.1%) |
Sep 2023 | - | -$6.09 M(+9.1%) | -$25.05 M(-2.7%) |
Jun 2023 | - | -$5.58 M(-20.9%) | -$25.75 M(-29.3%) |
Mar 2023 | - | -$7.06 M(+11.7%) | -$36.43 M(-28.9%) |
Dec 2022 | -$51.19 M(-43.3%) | -$6.32 M(-7.0%) | -$51.23 M(-25.2%) |
Sep 2022 | - | -$6.79 M(-58.2%) | -$68.46 M(-17.9%) |
Jun 2022 | - | -$16.26 M(-25.6%) | -$83.34 M(-6.2%) |
Mar 2022 | - | -$21.86 M(-7.1%) | -$88.87 M(-1.6%) |
Dec 2021 | -$90.32 M | -$23.54 M(+8.6%) | -$90.32 M(+3.1%) |
Sep 2021 | - | -$21.68 M(-0.5%) | -$87.63 M(-0.3%) |
Jun 2021 | - | -$21.78 M(-6.6%) | -$87.86 M(+4.2%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2021 | - | -$23.31 M(+11.8%) | -$84.35 M(+6.9%) |
Dec 2020 | -$78.89 M(+101.4%) | -$20.85 M(-4.8%) | -$78.89 M(+11.1%) |
Sep 2020 | - | -$21.91 M(+19.9%) | -$70.99 M(+19.0%) |
Jun 2020 | - | -$18.27 M(+2.3%) | -$59.65 M(+17.1%) |
Mar 2020 | - | -$17.86 M(+37.9%) | -$50.95 M(+30.1%) |
Dec 2019 | -$39.17 M(+223.2%) | -$12.95 M(+22.5%) | -$39.17 M(+30.3%) |
Sep 2019 | - | -$10.57 M(+10.4%) | -$30.06 M(+34.4%) |
Jun 2019 | - | -$9.57 M(+57.6%) | -$22.37 M(+44.9%) |
Mar 2019 | - | -$6.08 M(+58.1%) | -$15.43 M(+27.4%) |
Dec 2018 | -$12.12 M(+16.9%) | -$3.84 M(+33.7%) | -$12.12 M(+46.4%) |
Sep 2018 | - | -$2.87 M(+8.7%) | -$8.28 M(+53.2%) |
Jun 2018 | - | -$2.64 M(-4.2%) | -$5.40 M(+95.8%) |
Mar 2018 | - | -$2.76 M | -$2.76 M |
Dec 2017 | -$10.37 M | - | - |
FAQ
- What is Quince Therapeutics annual operating income?
- What is the all time high annual operating profit for Quince Therapeutics?
- What is Quince Therapeutics annual operating profit year-on-year change?
- What is Quince Therapeutics quarterly operating income?
- What is the all time high quarterly operating profit for Quince Therapeutics?
- What is Quince Therapeutics quarterly operating profit year-on-year change?
- What is Quince Therapeutics TTM operating income?
- What is the all time high TTM operating profit for Quince Therapeutics?
- What is Quince Therapeutics TTM operating profit year-on-year change?
What is Quince Therapeutics annual operating income?
The current annual operating profit of QNCX is -$27.14 M
What is the all time high annual operating profit for Quince Therapeutics?
Quince Therapeutics all-time high annual operating income is -$10.37 M
What is Quince Therapeutics annual operating profit year-on-year change?
Over the past year, QNCX annual operating income has changed by +$24.05 M (+46.98%)
What is Quince Therapeutics quarterly operating income?
The current quarterly operating profit of QNCX is -$8.55 M
What is the all time high quarterly operating profit for Quince Therapeutics?
Quince Therapeutics all-time high quarterly operating income is -$2.64 M
What is Quince Therapeutics quarterly operating profit year-on-year change?
Over the past year, QNCX quarterly operating income has changed by -$203.00 K (-2.43%)
What is Quince Therapeutics TTM operating income?
The current TTM operating profit of QNCX is -$34.40 M
What is the all time high TTM operating profit for Quince Therapeutics?
Quince Therapeutics all-time high TTM operating income is -$2.76 M
What is Quince Therapeutics TTM operating profit year-on-year change?
Over the past year, QNCX TTM operating income has changed by -$7.33 M (-27.06%)